From new product introductions to swiped trade secrets, chipmakers have stolen the spotlight so far this week. But let’s not forget about biotech stocks, five of which are highlighted in IBD’s Screen of the Day, Big Cap Leaders, along with their semiconductor counterparts. The large-cap biotechs include Celgene (CELG), Regeneron Pharmaceuticals (REGN) and Gilead Sciences (GILD) Celgene, which has a highest-possible IBD Composite Rating of 99,
Shares of highly rated drugmakers Celgene (CELG), Lannett (LCI) and Akorn (AKRX) rose Monday, while a pair of small drug companies plunged on negative reports. Celgene and its partner Acceleron Pharma (XLRN) said the Food and Drug Administration granted fast-track designation to luspatercept to treat patients who have the blood disease beta thalassemia as a result of transfusions or other causes. The FDA’s fast-track status allows a company to
After reporting mixed quarterly results, top-rated biotech Celgene (CELG) looks to have unraveled its base-building effort. The stock dropped 5% on the stock market today, falling to a four-month low. Celgene’s earnings grew 27% and beat estimates by a penny. Sales increased 20% but missed views. Group peer Biogen (BIIB) has yet to retake its 50-day line after it gapped below that area when Q1 results missed estimates last Friday. Will fellow